Literature DB >> 8266026

Meta-analysis of NSAIDs: contribution of drugs, doses, trial designs, and meta-analytic techniques.

P C Gøtzsche1.   

Abstract

To elucidate potential bias sources in meta-analyses, I studied whether the effect of nonsteroidal, anti-inflammatory drugs on joint count in patients with rheumatoid arthritis was related to trial design (active or placebo control), sample size, duration of treatment, drop-out rate, the existence of a wash-in period, drug, dose, and meta-analytic technique. In short-term trials, none of the covariates was related to the effect size. No differences between drugs or doses were found in usual gold standard meta-analyses, comparing drugs within trials before pooling. In a meta-analysis of treatment arms, however, four drugs were either significantly more or less effective than average, but these deviations were spurious. In meta-analyses of NSAIDs, indirect comparisons may allow a preliminary comparison of drugs that have not been compared directly. Treatment arms should be compared within trials before pooling, however.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8266026     DOI: 10.3109/03009749309095135

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  7 in total

Review 1.  Non-steroidal anti-inflammatory drugs.

Authors:  P C Gøtzsche
Journal:  BMJ       Date:  2000-04-15

Review 2.  NSAIDs.

Authors:  Peter C Gøtzsche
Journal:  BMJ Clin Evid       Date:  2007-06-01

3.  Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group.

Authors:  Ambuj Kumar; Heloisa Soares; Robert Wells; Mike Clarke; Iztok Hozo; Archie Bleyer; Gregory Reaman; Iain Chalmers; Benjamin Djulbegovic
Journal:  BMJ       Date:  2005-11-18

Review 4.  NSAIDs.

Authors:  Peter C Gøtzsche
Journal:  BMJ Clin Evid       Date:  2010-06-28

Review 5.  Optimal treatment of phantom limb pain in the elderly.

Authors:  R Baron; G Wasner; V Lindner
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

Review 6.  Managing early presentation of rheumatoid arthritis. Systematic overview.

Authors:  R Glazier
Journal:  Can Fam Physician       Date:  1996-05       Impact factor: 3.275

Review 7.  COX-2 inhibitors in rheumatoid arthritis.

Authors:  J S Sundy
Journal:  Curr Rheumatol Rep       Date:  2001-02       Impact factor: 4.686

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.